Teva Pharmaceutical Industries (TEVA) Assets Average (2009 - 2026)

Teva Pharmaceutical Industries has disclosed Assets Average across 17 years of filings, most recently posting $40.4 billion for Q1 2026.

• Quarterly Assets Average rose 3.92% year-over-year to $40.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40.4 billion (up 3.92% YoY) and the FY2025 annual result came in at $40.0 billion, down 3.3% from the prior year.
• Assets Average steadied at $40.4 billion in Q1 2026, from $40.3 billion in the prior quarter.
• Over five years, Assets Average peaked at $47.4 billion in Q1 2022 and troughed at $38.9 billion in Q1 2025.
• A 5-year average of $42.4 billion and a median of $42.6 billion in 2023 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2025 — Assets Average declined 9.87% — and 2026, when it grew 3.92%.
• Tracing TEVA's Assets Average over 5 years: stood at $44.1 billion in 2022, then fell by 3.05% to $42.8 billion in 2023, then retreated by 5.25% to $40.5 billion in 2024, then dropped by 0.59% to $40.3 billion in 2025, then advanced by 0.23% to $40.4 billion in 2026.
• Business Quant data shows TEVA's Assets Average at $40.4 billion in Q1 2026, $40.3 billion in Q4 2025, and $40.0 billion in Q3 2025.